ZS Pharma is committed to advancing patient care by developing new therapeutic compounds to treat serious conditions related to kidney, cardiovascular and liver diseases. Our lead investigational therapy, ZS-9, is a novel agent for the treatment of hyperkalemia, a potentially life-threatening condition characterized by abnormally high levels of potassium in the blood.
We are evaluating ZS-9 in a late-stage clinical trial program to demonstrate its ability to safely, effectively and rapidly remove excess potassium from the body. Learn more about our positive top-line results from the pivotal Phase 3 clinical trial in patients with hyperkalemia here.
Keep up to date with the latest ZS Pharma News and UpdatesSign Up
ZS Pharma to Present Results of Phase 2 Trial of ZS-9 at 2014 American College of Cardiology’s Annual Scientific SessionDownload PDF
ZS Pharma Announces Start of Enrollment of Phase 3 Extended Dosing Study of ZS-9 in Patients with HyperkalemiaDownload PDF
ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for HyperkalemiaDownload PDF